Chaos rocks Parliament as Rahul Gandhi’s citation of ex-Army chief MM Naravane’s unpublished memoir on the 2020 Ladakh face-off triggers furious BJP pushback, forcing repeated disruptions in the Lok ...

Pakistan witnessed one of the deadliest days in Balochistan in decades as coordinated suicide bombings and militant attacks by the Balochistan Liberation Army (BLA) targeted civilians and security ...

- Priority Review designation is granted to applications for drugs that, if approved, would be a significant improvement in the safety or effectiveness of treating a serious condition - - Veligrotug ...

Shares in Kyverna Therapeutics rose in premarket trading after the company said it plans to submit a biologics license application to the Food and Drug Administration for miv-cel, its treatment for ...

Summit Therapeutics plans to file for a key FDA approval by the end of this year. The drugmaker is betting that the FDA will change its mind on guidance already handed down. The agency's decision is a ...

Start with the structure. At 18, Tatis took a $2 million advance from BLA in exchange for 10% of all future baseball earnings. Then came the life-changing Padres extension in February 2021: 14 years, ...

San Diego Padres star Fernando Tatis Jr. has been ordered by an arbitrator to pay Big League Advance (BLA) $3.74 million. BLA recently petitioned the Superior Court of District of Columbia to confirm ...

Having already altered the journey of its rare disease gene therapy to a hoped-for FDA approval, Rocket Pharmaceuticals has now aborted the mission entirely. The biotech initiated a rolling biologics ...

Big League Advance Fund recently petitioned the Superior Court of District of Columbia to confirm an arbitration award against San Diego Padres outfielder Fernando Tatis Jr., who has been ordered to ...

Please provide your email address to receive an email when new articles are posted on . Ocugen plans to submit biologics license applications for retinitis pigmentosa, Stargardt disease and geographic ...

The FDA rejected a supplemental Biologics License Application (sBLA) for glofitamab-gxbm (Columvi, Genentech) in combination with gemcitabine and oxaliplatin for the second-line treatment of relapsed ...